Finding 1147101 (2023-005)

Material Weakness Repeat Finding
Requirement
L
Questioned Costs
-
Year
2023
Accepted
2025-07-08
Audit: 361679
Organization: Tuerk House, Inc. (MD)

AI Summary

  • Core Issue: The Organization's annual expenditure reporting did not match the actual grant expenditures, leading to inaccuracies in quarterly programmatic reports.
  • Impacted Requirements: Compliance with reporting standards under 45 CFR 75.342 was not met due to lack of internal controls.
  • Recommended Follow-Up: Management should implement a review process for reports to ensure accuracy and proper documentation before submission.

Finding Text

Opioid STR ALN No. 93.788 U.S. Department of Health and Human Services Criteria or Specific Requirement – Reporting (45 CFR 75.342) Condition – The Organization’s annual expenditure reporting did not agree to the underlying grant expenditure support. In addition, the Organization did not properly report certain information in its quarterly programmatic reports. Cause – The Organization did not have necessary internal controls to properly identify and report eligible grant expenditures. In addition, the Organization did not have controls in place to support amounts reported in quarterly programmatic reporting requirements. Effect or potential effect– The Organization incorrectly reported grant expenditures and programmatic statistics, such as total unique patients. Questioned Costs – None Context – A sample of one financial report was tested out of the total population of 2 financial reports. In addition, a sample of one special report was tested out of the total population of 4 special reports. The sampling methodology used is not and is not intended to be statistically valid. Certain amounts on the financial and special reports were not accurately reported. Identification as a repeat finding, if applicable – Repeat finding (see 2022-005) Recommendation – Management should review the required reports for accuracy prior to submission to ensure the documentation supports the amounts in the report.

Categories

Reporting Internal Control / Segregation of Duties

Other Findings in this Audit

  • 570656 2023-003
    Material Weakness Repeat
  • 570657 2023-003
    Material Weakness Repeat
  • 570658 2023-004
    Material Weakness Repeat
  • 570659 2023-005
    Material Weakness Repeat
  • 1147098 2023-003
    Material Weakness Repeat
  • 1147099 2023-003
    Material Weakness Repeat
  • 1147100 2023-004
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.788 Opioid Str $2.66M
93.959 Block Grants for Prevention and Treatment of Substance Abuse $1.40M
95.007 Research and Data Analysis $228,817
21.019 Coronavirus Relief Fund $50,000